Gatti, Milo http://orcid.org/0000-0003-3018-3779
Pea, Federico http://orcid.org/0000-0002-6966-7167
Funding for this research was provided by:
Alma Mater Studiorum - UniversitĂ di Bologna
Article History
Accepted: 18 May 2021
First Online: 14 June 2021
Declarations
:
: Open access funding provided by Alma Mater Studiorum - UniversitĂ di Bologna within the CRUI-CARE Agreement.
: Federico Pea participated in speakers’ bureaus for Angelini, Basilea Pharmaceutica, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Pfzer and Sanofi Aventis, and in advisory boards for Angelini, Basilea Pharmaceutica, Correvio, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Novartis, Pfzer, Shionogi and Thermo-Fisher. Milo Gatti has no conflicts of interest to declare.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MG and FP made substantial contributions to the conception of the manuscript. MG was involved in drafting the manuscript, and FP made substantial contributions in revising the manuscript critically for important intellectual content. All authors approved the final version of the manuscript.